DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Germany
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
SRT3 logo

Sartorius Aktiengesellschaft Stock Price

XTRA:SRT3 Community·€14.7b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 16 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

SRT3 Share Price Performance

€236.80
37.25 (18.67%)
​
€260.05
Fair Value
€236.80
37.25 (18.67%)
8.9% undervalued intrinsic discount
€260.05
Fair Value
Price €236.80
AnalystConsensusTarget €260.05
AnalystLowTarget €191.20
AnalystHighTarget €310.00
Thu, 4 Sep 25
Fair Value€260.05
Share Pricen/a

SRT3 Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value €260.05 8.9% undervalued intrinsic discount

Advanced Biologic Adoption Will Expand Global Reach

0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value €191.2 23.8% overvalued intrinsic discount

Rising Tariffs, Regulatory Hurdles And Cost Pressures Will Squeeze Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value €310 23.6% undervalued intrinsic discount

Cell And Gene Therapies Will Expand Secular Bioproduction

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
SRT3 logo
Sartorius
23.8% overvalued intrinsic discount

Rising Tariffs, Regulatory Hurdles And Cost Pressures Will Squeeze Margins

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Published 23 Jun 2025
Read Narrative
SRT3 logo
Sartorius
23.6% undervalued intrinsic discount

Cell And Gene Therapies Will Expand Secular Bioproduction

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Published 11 Jun 2025
Read Narrative
SRT3 logo
Sartorius
8.9% undervalued intrinsic discount

Advanced Biologic Adoption Will Expand Global Reach

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 1 May 2025
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
SRT3 logo

Rising Tariffs, Regulatory Hurdles And Cost Pressures Will Squeeze Margins

Fair Value: €191.2 23.8% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
SRT3 logo

Cell And Gene Therapies Will Expand Secular Bioproduction

Fair Value: €310 23.6% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
SRT3 logo

Advanced Biologic Adoption Will Expand Global Reach

Fair Value: €260.05 8.9% undervalued intrinsic discount
8 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Reasonable growth potential with proven track record.

1 Risk
3 Rewards
View Full Analysis

Sartorius Aktiengesellschaft Key Details

€3.6b

Revenue

€1.9b

Cost of Revenue

€1.6b

Gross Profit

€1.4b

Other Expenses

€196.1m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Oct 22, 2026
2.84
45.71%
5.48%
96.4%
View Full Analysis

About SRT3

Founded
1870
Employees
14279
CEO
Michael Grosse
WebsiteView website
www.sartorius.com

Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and retrieval, live-cell imaging and analysis systems, and surface plasmon resonance systems; cell culture solutions, including bioreactors and fermenters, cell culture reagents, supplements and matrices, nucleic acid and delivery solutions, cell culture media, and cell lines and buffers; and fluid management products. It also provides lab filtration and purification solutions, lab water purification systems, microtissue technologies, lab weighing, pipettes, tips and dispensers, microbiological testing solutions, lab data and fleet management software, and OEM solutions; and Process chromatography and filtration solutions. The company serves the life science research, biopharmaceutical manufacturing, cell and gene therapy, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.

Recent SRT3 News & Updates

Recent updates

No updates

Sartorius Aktiengesellschaft Competitors

MRK logo

Merck KGaA

Symbol: XTRA:MRK
Market cap: €57.9b
BAYN logo

Bayer

Symbol: XTRA:BAYN
Market cap: €48.6b
1SXP logo

SCHOTT Pharma KGaA

Symbol: XTRA:1SXP
Market cap: €3.5b
DMP logo

Dermapharm Holding

Symbol: XTRA:DMP
Market cap: €1.9b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide